Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Quince gains right for EryDel's Phase 3 lead asset, EryDex (dexamethasone sodium phosphate), targeting a rare fatal pediatric neurological disease, Ataxia-Telangiectasia (A-T), which currently has no approved treatments.
Lead Product(s): Dexamethasone Sodium Phosphate
Therapeutic Area: Genetic Disease Product Name: EryDex
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Quince Therapeutics
Deal Size: $485.0 million Upfront Cash: $485.0 million
Deal Type: Acquisition October 23, 2023
Details:
Through the acquisition, Quince gains right for EryDel's Phase 3 lead asset, EryDex (dexamethasone sodium phosphate), targeting a rare fatal pediatric neurological disease, Ataxia-Telangiectasia (A-T), which currently has no approved treatments.
Lead Product(s): Dexamethasone Sodium Phosphate
Therapeutic Area: Genetic Disease Product Name: EryDex
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Quince Therapeutics
Deal Size: $485.0 million Upfront Cash: $485.0 million
Deal Type: Acquisition July 24, 2023